This review evaluates the efficacy of ripretinib in the management of gastrointestinal stromal tumors (GISTs), rare mesenchymal neoplasms. These tumors are primarily caused by mutations in the KIT proto-oncogene (CD117) or platelet-derived growth factor receptor alpha (PDGFRA) gene. The introduction of tyrosine kinase inhibitors (TKIs) such as imatinib has improved the treatment of GIST. However, the resistance to these TKIs has become a major impediment to its clinical management, particularly due to the occurrence of secondary resistance mutations in the KIT gene. Ripretinib, a novel switch-control inhibitor, represents a new-generation TKI designed to overcome this challenge. By targeting the switch pocket and activation loop, it has been reported to inhibit various KIT mutations, including secondary resistance mutations, as well as PDGFRA mutations. Clinical trials have demonstrated that ripretinib significantly prolongs progression-free and overall survival in patients who have failed third-line or later treatments. It also improves objective response rate and durability of response, with manageable adverse effects such as alopecia and fatigue. Emerging data further suggest mutation-specific efficacy, particularly in exon 11 and exon 17/18 combinations, highlighting the potential for personalized therapy. This review highlights the development, mechanism of action, and key clinical outcomes of ripretinib, with an emphasis on its potential to overcome resistance and its role in personalized GIST therapy.
- Open Access
- Review
Therapeutic Role of Ripretinib in Gastrointestinal Stromal Tumor: A Next-Generation Tyrosine Kinase Inhibitor Addressing Resistance and Mutation Diversity
- Jongmin Choi,
- Sun-Young Han *
Author Information
Received: 06 Aug 2025 | Revised: 06 Nov 2025 | Accepted: 28 Nov 2025 | Published: 24 Mar 2026
Abstract
Keywords
gastrointestinal stromal tumor | KIT | tyrosine kinase inhibitor | ripretinib
References
- 1.
Schaefer, I.M.; DeMatteo, R.P.; Serrano, C. The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor. Am. Soc. Clin. Oncol. Educ. Book 2022, 42, 1–15.
- 2.
Kang, Y.K.; Kang, H.J.; Kim, K.M.; Sohn, T.; Choi, D.; Ryu, M.H.; Kim, W.H.; Yang, H.K.; Korean, G.S.G. Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. Cancer Res. Treat. 2012, 44, 85–96.
- 3.
Di Vito, A.; Ravegnini, G.; Gorini, F.; Aasen, T.; Serrano, C.; Benuzzi, E.; Coschina, E.; Monesmith, S.; Morroni, F.; Angelini, S.; et al. The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib. Pharmacol. Ther. 2023, 248, 108475.
- 4.
Smith, B.D.; Kaufman, M.D.; Lu, W.P.; Gupta, A.; Leary, C.B.; Wise, S.C.; Rutkoski, T.J.; Ahn, Y.M.; Al-Ani, G.; Bulfer, S.L.; et al. Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer Cell 2019, 35, 738–751.
- 5.
Foster, B.M.; Zaidi, D.; Young, T.R.; Mobley, M.E.; Kerr, B.A. CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance. Biomedicines 2018, 6, 31.
- 6.
Wang, L.; Felix, J.C.; Lee, J.L.; Tan, P.Y.; Tourgeman, D.E.; O’Meara, A.T.; Amezcua, C.A. The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus. Gynecol. Oncol. 2003, 90, 402–406.
- 7.
Roskoski, R., Jr. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders. Pharmacol. Res. 2018, 133, 35–52.
- 8.
Liu, P.; Tan, F.; Liu, H.; Li, B.; Lei, T.; Zhao, X. The Use of Molecular Subtypes for Precision Therapy of Recurrent and Metastatic Gastrointestinal Stromal Tumor. Onco Targets Ther. 2020, 13, 2433–2447.
- 9.
Hwang, D.G.; Qian, X.; Hornick, J.L. DOG1 antibody is a highly sensitive and specific marker for gastrointestinal stromal tumors in cytology cell blocks. Am. J. Clin. Pathol. 2011, 135, 448–453.
- 10.
Wu, C.E.; Tzen, C.Y.; Wang, S.Y.; Yeh, C.N. Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View. Cancers 2019, 11, 679.
- 11.
Rahman, J.; Rahmanuddin, S.; Sham, S.; Sonawane, S. Extensive Degenerative Change Masquerading Histomorphology in a Giant Cystic Gastrointestinal Stromal Tumor With Rare PDGFRA Mutation. Cureus 2020, 12, e10772.
- 12.
Sanlorenzo, M.; Vujic, I.; Posch, C.; Ma, J.; Lin, K.; Lai, K.; Lee, D.; Vujic, M.; Oses-Prieto, J.A.; Chand, S.; et al. Oncogenic KIT mutations in different exons lead to specific changes in melanocyte phospho-proteome. J. Proteom. 2016, 144, 140–147.
- 13.
Calderillo-Ruiz, G.; Perez-Yepez, E.A.; Garcia-Gamez, M.A.; Millan-Catalan, O.; Diaz-Romero, C.; Ugalde-Silva, P.; Salas-Benavides, R.; Perez-Plasencia, C.; Carbajal-Lopez, B. Genomic profiling in GIST: Implications in clinical outcome and future challenges. Neoplasia 2024, 48, 100959.
- 14.
Janku, F.; Abdul Razak, A.R.; Chi, P.; Heinrich, M.C.; von Mehren, M.; Jones, R.L.; Ganjoo, K.; Trent, J.; Gelderblom, H.; Somaiah, N.; et al. Switch Control Inhibition of KIT and PDGFRA in Patients with Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. J. Clin. Oncol. 2020, 38, 3294–3303.
- 15.
Blay, J.Y.; Serrano, C.; Heinrich, M.C.; Zalcberg, J.; Bauer, S.; Gelderblom, H.; Schoffski, P.; Jones, R.L.; Attia, S.; D’Amato, G.; et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020, 21, 923–934.
- 16.
Lim, S.Y.; Ferro-Lopez, L.; Barquin, E.; Lindsay, D.; Thway, K.; Smith, M.J.; Benson, C.; Jones, R.L.; Napolitano, A. Efficacy and Safety of Ripretinib in Advanced Gastrointestinal Stromal Tumors within an Expanded Access Program: A Cohort Study. Cancers 2024, 16, 985.
- 17.
Bauer, S.; Jones, R.L.; Blay, J.Y.; Gelderblom, H.; George, S.; Schoffski, P.; von Mehren, M.; Zalcberg, J.R.; Kang, Y.K.; Razak, A.A.; et al. Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial. J. Clin. Oncol. 2022, 40, 3918–3928.
- 18.
Li, J.; Cai, S.; Zhou, Y.; Zhang, J.; Zhou, Y.; Cao, H.; Wu, X.; Deng, Y.; Huang, Z.; Dong, J.; et al. Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study. Clin. Cancer Res. 2022, 28, 3425–3432.
- 19.
Kumar, S.S.; Philip, A.; Pavithran, K. Ripretinib. CancerRes.Stat. Treat. 2021, 4, 93–98.
- 20.
Li, X.; Shelton, M.J.; Wang, J.; Meade, J.; Ruiz-Soto, R. Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor. Clin. Pharmacol. Drug Dev. 2022, 11, 1165–1176.
- 21.
George, S.; Blay, J.-Y.; Chi, P.; Jones, R.L.; Serrano, C.; Somaiah, N.; Reichmann, W.; Sprott, K.; Achour, H.; Sherman, M.L.; et al. INSIGHT: A phase 3, randomized, multicenter, open-label study of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib harboring KIT exon 11 + 17 and/or 18 mutations. J. Clin. Oncol. 2023, 41, TPS11582.
- 22.
Chandana, S.R.; Shepard, D.R.; Mehnert, J.M.; Chi, P.; Trent, J.C.; Psoinos, C.M.; Zhou, B.; Black, V.; Viswanathan, L.; Gozo, M.; et al. DCC-3116 in combination with ripretinib for patients with advanced gastrointestinal stromal tumor: A phase 1/2 study. J. Clin. Oncol. 2024, 42, TPS11587.
- 23.
Heinrich, M.C.; Jones, R.L.; George, S.; Gelderblom, H.; Schoffski, P.; von Mehren, M.; Zalcberg, J.R.; Kang, Y.K.; Razak, A.A.; Trent, J.; et al. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial. Nat. Med. 2024, 30, 498–506.
- 24.
Liao, W.; Xu, H.; Hutton, D.; Wu, Q.; Zhou, K.; Luo, H.; Lei, W.; Feng, M.; Yang, Y.; Wen, F.; et al. Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors. Front. Oncol. 2021, 11, 692005.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Suite 4002 Level 4, 447 Collins Street, Melbourne, Victoria 3000, Australia
General Inquiries: info@sciltp.com